…in the Eastern District of Virginia on May 11, 2021 filing a declaratory judgment action on four of 62 patents asserted against them by AbbVie. In this second action, AbbVie…
…in the Eastern District of Virginia on May 11, 2021 filing a declaratory judgment action on four of 62 patents asserted against them by AbbVie. In this second action, AbbVie…
As we previously reported, in April 2021, Amgen petitioned for the full Federal Circuit to reconsider the decision of a three-judge panel that two of Amgen’s patents, U.S. Patent Nos….
An article published last week in Scientific Reports describes the results of a multicenter prospective study evaluating the safety and efficacy of switching IBD patients from Abbvie’s Humira product to…
…U.S. ZYTIGA (abiraterone acetate). Also at the end of April, Amgen reported a total revenue decrease of 4% to $5.9 billion in comparison to the first quarter of 2020. Amgen…
On May 11, 2021, Alvotech USA and Alvotech hf (jointly, Alvotech) filed a complaint seeking declaratory judgement against AbbVie Inc. and AbbVie Biotechnology Ltd (jointly, AbbVie) in the Eastern District…
On May 4, 2021, Amgen Canada announced the launch of their adalimumab biosimilar AMGEVITA (reference drug HUMIRA) for the treatment of 11 chronic inflammatory conditions. AMGEVITA is available as a…
On April 20, 2021, Korean company Huon Labs announced that it will develop a PROLIA biosimilar using PanGen Biotech’s cell culture and purification technology. PROLIA (denosumab), an Amgen product, is…
…as a matter of law that the asserted claims of two of Amgen’s patents, U.S. Patent Nos. 8,829,165 (the “’165 patent”) and 8,859,741 (the “’741 patent”), covering its cholesterol-lowering drug…
…based on Amgen’s concessions made during patent prosecution.” Defendants argued that the present case should be dismissed for similar reasons. Plaintiffs responded in their Answering Brief that Amgen “did not…
…(MEfRVO). While there are currently no approved biosimilars to Eylea®, Alteogen (ALT-L9), Mylan (MYL-1701P), Samsung Bioepis (SB15), Amgen (ABP 938), Formycon (FYB203), and Coherus Biosciences (CHS-2020) are developing such biosimilars….